Stock Analiz

Xenon Pharmaceuticals Inc. (XENE) financials: revenue, earnings and cash flow

Fiscal 2016–2025 · from SEC filings · data as of November 13, 2026

Summary

Xenon Pharmaceuticals’s revenue went from $2M in fiscal 2016 to $8M in fiscal 2025, growth of about 17.2% a year.

Net income in fiscal 2025 was -$346M, a net margin of -4612.1%; the best year in this period was 2016 with -$23M.

Free cash flow was -$280M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 412% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $2M162017: $311000172019: $7M192020: $32M202021: $18M212022: $9M222023: $0232024: $0242025: $8M25$8M
Net income
2016: -$23M162017: -$31M172018: -$34M182019: -$42M192020: -$29M202021: -$79M212022: -$125M222023: -$182M232024: -$234M242025: -$346M25-$346M
Free cash flow
2016: -$20M162017: -$29M172018: -$35M182019: -$6M192020: -$51M202021: -$72M212022: -$104M222023: -$157M232024: -$184M242025: -$280M25-$280M
EPS (diluted)
2016: $-1.48162017: $-1.72172018: $-1.63182019: $-1.54192020: $-0.81202021: $-1.77212022: $-2.06222023: $-2.73232024: $-3.01242025: $-4.3625$-4.36

Income statement

Fiscal year2025202420232022202120202019201820172016
Revenue$8M$0$0$9M$18M$32M$7M—$311000$2M
Gross profit——————————
Operating income-$373M-$279M-$214M-$129M-$79M-$31M-$43M-$38M-$33M-$25M
Net income-$346M-$234M-$182M-$125M-$79M-$29M-$42M-$34M-$31M-$23M
EPS (diluted)$-4.36$-3.01$-2.73$-2.06$-1.77$-0.81$-1.54$-1.63$-1.72$-1.48
R&D$301M$210M$168M$106M$75M$51M$39M$24M$26M$20M
Revenue growth——−100.0%−48.8%−42.7%+371.0%——−82.8%−88.4%

Cash flow

Fiscal year2025202420232022202120202019201820172016
Operating cash flow-$279M-$181M-$151M-$101M-$70M-$48M-$5M-$35M-$29M-$20M
Capital spending-$799000-$3M-$6M-$3M-$2M-$3M-$1M-$507000-$315000-$279000
Free cash flow-$280M-$184M-$157M-$104M-$72M-$51M-$6M-$35M-$29M-$20M
Dividends paid$0$0$0$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay$54M$51M$32M$20M$10M$6M$3M$3M$2M$2M

Balance sheet

Fiscal year2025202420232022202120202019201820172016
Cash$549M$627M$638M$592M$552M$177M$141M$119M$44M$64M
Debt$8M$9M$11M$10M$8M$3M$16M$16M$7M—
Equity$582M$755M$928M$721M$550M$171M$92M$103M$36M$64M
Total assets$633M$798M$965M$754M$572M$189M$148M$122M$46M$67M
Shares (diluted)79M78M67M61M44M35M26M19M18M15M

Margins and returns

Fiscal year2025202420232022202120202019201820172016
Gross margin——————————
Operating margin-4974.3%——-1368.9%-428.5%-97.3%-627.0%—-10474.3%-1376.4%
Net margin-4612.1%——-1329.0%-427.9%-89.6%-609.1%—-9872.7%-1275.5%
FCF margin-3732.2%——-1101.6%-388.1%-157.8%-87.2%—-9337.9%-1100.7%
ROIC-50.0%-35.9%-22.8%-13.9%-14.1%-17.8%-39.5%-32.0%-59.9%-30.7%
ROE-59.5%-31.0%-19.7%-17.4%-14.3%-16.8%-45.2%-33.4%-85.5%-36.0%

Frequently asked questions

What is Xenon Pharmaceuticals’s annual revenue?

$8M in fiscal 2025.

How much profit does Xenon Pharmaceuticals make?

Net income was -$346M in fiscal 2025 (net margin -4612.1%).

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.